Cancer Drug Parity Act of 2021
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Cancer Drug Parity Act of 2021
This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
Referred to the House Committee on Education and Labor.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 4385: Cancer Drug Parity Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-4385/
"H.R. 4385: Cancer Drug Parity Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-4385/.
H.R. 4385, 117th Cong. (2026), https://openamerica.io/bill/117-HR-4385/.
[H.R. 4385: Cancer Drug Parity Act of 2021](https://openamerica.io/bill/117-HR-4385/)